StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc.

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$682.65−14.35 (-2.06%)

Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%

Thermo Fisher Scientific Segment Income Margin — Specialty Diagnostics by Quarter

Segment Income Margin — Specialty Diagnostics (%)

QuarterlyAnnual

Thermo Fisher Scientific Segment Income Margin — Specialty Diagnostics: 31.0% in Q3 2026, up 3.6 pts from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q3 2026
31.0%
Period ended Sep 30, 2026
Change on a year earlier
+3.6 pts
27.4% in Q3 2025
History
20 quarters
Since Q3 2021
Sources
8
Documents cited below

Where the Q3 2026 figure comes from

“SD: Segment income margin 26.5% 27.0% 27.4% 26.6% 26.9% 27.4% 27.7% 31.0%”

Source: Q3 2026 Reconciliation of Financial Information ↗

Reported in IR Financial Reconciliation Package & SEC MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSegment Income Margin — Specialty Diagnostics (%)Year on yearSource
Q3 2026Sep 30, 202631.0%+3.6 ptsQ3 2026 Reconciliation of Financial Information ↗
Q2 2026Jun 30, 202627.7%+0.7 ptsQ3 2026 Reconciliation of Financial Information ↗
Q1 2026Mar 31, 202627.4%+0.9 ptsQ3 2026 Reconciliation of Financial Information ↗
Q4 2025Dec 31, 202526.6%+3.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q3 2025Sep 30, 202527.4%+1.5 ptsQ3 2026 Reconciliation of Financial Information ↗
Q2 2025Jun 30, 202527.0%+0.3 ptsQ3 2026 Reconciliation of Financial Information ↗
Q1 2025Mar 31, 202526.5%0.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q4 2024Dec 31, 202423.6%-0.3 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q3 2024Sep 30, 202425.9%-0.2 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q2 2024Jun 30, 202426.7%0.0 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q1 2024Mar 31, 202426.5%+1.2 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q4 2023Dec 31, 202323.9%+5.3 ptsQ4 & FY2024 Reconciliation of Financial Information ↗
Q3 2023Sep 30, 202326.1%+5.5 ptsQ4 & FY2024 Reconciliation of Financial Information ↗
Q2 2023Jun 30, 202326.7%+4.6 ptsQ4 & FY2024 Reconciliation of Financial Information ↗
Q1 2023Mar 31, 202325.3%+1.4 ptsQ4 & FY2024 Reconciliation of Financial Information ↗
Q4 2022Dec 31, 202218.6%–SEC Form 8-K (8k_2023Q4, filed 2024-01-31) ↗

Cite this data

StockData. (2026). Thermo Fisher Scientific Segment Income Margin — Specialty Diagnostics (%), quarterly Q3 2021–Q3 2026 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/seg-margin-sd

See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.